炎症性腸疾患（IBD）は厚生労働省指定難病であり，最も患者数の多い疾患の一つである．完治を目指すことが難しい疾患であり，以前は治療薬も少なく寛解維持に難渋していた．近年，治療薬の開発により保険適応となる薬剤が増えてきており，異なる標的薬剤の登場は治療選択の幅を広げている．さらに，類似した標的の薬剤である同種同効薬も複数使用可能となり，選択が増える一方で最適な治療選択に苦慮することが新たな問題として出てきている．罹病期間が長いことから，個々の患者の学業，就業，出産，育児など様々なライフイベントを考慮した長期的な寛解維持を目指した治療戦略が必要である．本セッションでは益々多様化する患者に対して治療をいかに選択して最適化するかという課題の克服に向けて議論し，現状を理解し，将来展望を共有する場としたい．

Inflammatory bowel disease (IBD) is an intractable disease and is one of the most numerous diseases designated by the Ministry of Health, Labour and Welfare (MHLW). Previously, it was very difficult to maintain remission because of few therapeutic agents. In recent years, an increasing number of drugs with different targeted agents covered by social insurance has expanded the range of therapeutic options. Furthermore, the availability of several similarly targeted drugs with the same effect has increased the number of choices but has also raised a further issue of difficulty in selecting the most appropriate treatment. Due to the long disease duration, treatment strategies aimed at maintaining long-term remission are required, considering the various life events of individual patients, such as education, working, childbirth and childcare. This session will provide an opportunity to discuss how to overcome the challenges of selecting and optimizing treatment for an ever-diversifying patient population, to understand the current situation and to share future perspectives.